New Stem Cell Reports Perspective: Biomanufacturing in Low Earth Orbit

A new perspective article just published in Stem Cell Reports, “Biomanufacturing in low Earth orbit: A paradigm shift,” features insights from the ISS National Laboratory’s very own Program Director for In-Space Biomanufacturing Davide Marotta, Deputy Chief Scientist Donna Roberts, and Chief Scientist Michael Roberts, as well as leading researchers in regenerative medicine.

This Exciting New Article Highlights:

  • The rapid rise of biomedical R&D and in-space biomanufacturing on the ISS accelerating breakthrough advances in stem cell research and tissue engineering made possible by the novel environment of microgravity.
  • The role of key partners and new partnerships—including universities, biotechnology and pharmaceutical firms, and spaceflight hardware pioneers—joining with NASA and other government agencies to create new capabilities in low Earth orbit (LEO).
  • The emergence of in-space biomanufacturing as an engine to catalyze innovation off Earth to improve health outcomes on Earth and create a new marketplace in LEO.

Why This Matters

  • Microgravity as a catalyst: The article underscores how the space station’s environment boosts tissue formation, enhances the accuracy of or accelerates disease modeling, and supports the precision production of biologic therapies.
  • From discovery to delivery: Advances made in LEO could transform manufacturing processes for therapeutics—making drugs more effective, scalable, and affordable for patients on Earth (and eventually, beyond).
  • A collaborative pathway forward: The authors call for aligned investment, supportive policies, and cross-sector partnerships to scale space-based biomanufacturing into an impactful, new frontier in healthcare.

Under the management of the Center for the Advancement of Science in Space® (CASIS®), the ISS National Lab has been the engine driving this expansion of space-enabled biomedical innovation—supporting dozens of projects that explore stem cell growth, organoid disease modeling, tissue engineering, and in-space manufacturing.

This latest publication amplifies our mission: to position the ISS not just as a science lab in orbit, but as a burgeoning marketplace for therapeutics that can benefit humanity—today and for generations to come.

Read the full perspective to explore how space-based biomanufacturing is reshaping regenerative medicine and accelerating our journey toward better therapies.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Animal-Free 3D Fat-Immune Cell Model to Study Inflammation